Blood Plasma Derivatives Industry Forecast 2025-2034: Market Expansion, Trends, and Competitive Landscape

How large is the blood plasma derivatives  market, and what is its growth trajectory?

The blood plasma derivatives market size has grown strongly in recent years. It will grow from $51.81 billion in 2024 to $56.24 billion in 2025 at a compound annual growth rate (CAGR) of 8.6%.  The growth in the historic period can be attributed to increased prevalence of hemophilia and bleeding disorders, growth in geriatric population, increased awareness and diagnosis, rise in surgical procedures, global blood transfusion services

The blood plasma derivatives market size is expected to see strong growth in the next few years. It will grow to $80.42 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%.  The growth in the forecast period can be attributed to emergence of rare diseases therapies, growth in chronic diseases, increasing healthcare expenditure, patient-centric treatment approaches, growing healthcare infrastructure. Major trends in the forecast period include advancements in fractionation technologies, patient-centric approaches, collaborations and partnerships, expanding applications in neurology, technological innovations in plasma fractionation.

Get Your Free Sample of The Global Blood Plasma Derivatives  Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12107&type=smp

What are the key forces behind the blood plasma derivatives  market's growth in recent years?

The increasing prevalence of immunodeficiency disorders is expected to drive the growth of the blood plasma derivatives market. Immunodeficiency disorders are illnesses that either completely or partially compromise the immune system. Blood plasma derivatives find application in treating a multitude of medical conditions, including immune deficiency disorders. Plasma, a solution consisting of proteins and salts, encompasses over 100 different proteins, among which immunoglobulins are particularly utilized for addressing primary immunodeficiencies. Poor nutrition or malnutrition leads to macro- and micronutrient deficiencies, which can lead to immunodeficiency. For instance, in March 2022, according to the Allergy, Asthma & Clinical Immunology, the most common condition was Common Variable Immunodeficiency (CVID), affecting 16.6% of individuals in the US, 12.9% internationally, and 13.9% worldwide. Therefore, the increasing prevalence of immune deficiency disorders is driving the growth of the blood plasma derivatives market.

What are the major segments of the blood plasma derivatives  market?
The blood plasma derivatives market covered in this report is segmented –

1) By Type: Albumin, Factor VIII, Factor IX, Immunoglobulin, Hyperimmune Globulin, Other Types
2) By Application: Hemophilia, Hypogammaglobulinemia, Immunodeficiency Diseases, Von Willebrand's Disease, Other Applications
3) By End-User: Hospitals, Clinics, Other End-Users

Subsegments:
1) By Albumin: Human Serum Albumin, Recombinant Albumin
2) By Factor VIII: Plasma-Derived Factor VIII, Recombinant Factor VIII
3) By Factor IX: Plasma-Derived Factor IX, Recombinant Factor IX
4) By Immunoglobulin: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)
5) By Hyperimmune Globulin: Specific Pathogen-Reduced Hyperimmune Globulin, Standard Hyperimmune Globulin
6) By Other Types: Fibrinogen, Clotting Factor Concentrates, Plasma-Derived Proteins

Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/blood-plasma-derivatives-global-market-report

Which companies dominate the blood plasma derivatives  market?
Major companies operating in the blood plasma derivatives market include  Bayer AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Limited, Meiji Group, Grifols S.A., Shire Pharmaceuticals Inc., GC Biopharma Corp, Emergent BioSolutions Inc., Shanghai Raas Blood Products Co Ltd., Kedrion S.p.A., Sanquin, Biotest AG, Bio Products Ltd., ADMA Biologics Inc., China Biologic Products Holdings Inc., BioIVT, PlasmaGen BioSciences Pvt. Ltd., Virchow Biotech Private Limited, LFB S.A., Intas Pharmaceuticals Ltd., Octapharma Plasma

What major trends will shape the blood plasma derivatives  market during the forecast period?
Major companies operating in the blood plasma derivatives market are focused on adopting strategic partnerships to gain a competitive edge in the market. With this partnership, patients in need will have access to a steady and dependable supply of these vital plasma-derived medications, helping to meet the increasing need for immunoglobulins in France and beyond. For instance, in January 2022, Kedrion S.p.A. an Italy-based biopharmaceutical company specializing in the development, production, and distribution of plasma-derived therapies partnered with LPB, a UK-based pharmaceutical company specializing in biological medicinal products. Kedrion will use LFB plasma obtained in France by the Etablissement Français du Sang (EFS) to produce immunoglobulins in Hungary. The current supply of immunoglobulins, which will be made available to hospitals across the nation in accordance with and under the supervision of French health authorities, will be supplemented by these imports from LFB in France.

What are the key regional dynamics of the blood plasma derivatives  market, and which region leads in market share?
North America was the largest region in the blood plasma derivatives market in 2024. The regions covered in the blood plasma derivatives market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Does The Blood Plasma Derivatives  Market Report 2025 Offer?
The blood plasma derivatives  market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.

Blood plasma derivatives are medicinal products crafted from refined proteins found in blood plasma, encompassing clotting factors, albumins, and other proteins employed to treat diverse medical ailments. These derivatives hold significant significance as they aid in replenishing absent or inadequate proteins within the body.

Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12107

About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.

Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model